Clinical Trials Logo
  1. Home
  2. Restenosis
  3. NCT01735825

Treatment of Coronary In-Stent Restenosis — TIS  

Restenosis Clinical Trial

Official title:
Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Drug Eluting Paclitaxel-coated Balloon and Drug Eluting Stent With Everolimus.

Clinical Trial Summary

The purpose of this study is to compare efficacy of coronary in-stent restenosis therapy using drug eluting paclitaxel-coated balloon catheters with the latest generation of drug eluting stents releasing everolimus.

Clinical Trial Description

In-stent restenosis after coronary angioplasty is currently one of the main limitations of this method, leading to a recurrence of exertional angina pectoris or manifesting as acute coronary syndrome. Histopathologic substrate of in-stent restenosis is neointimal hyperplasia. Repeated plain balloon angioplasty or using cutting balloon catheters in the treatment of in-stent restenosis does not achieve satisfactory results. Brachytherapy, used in the past, it has also abandoned. The current treatment of in-stent restenosis is the use of drug eluting stents. Local drug released from these stents prevents new neointimal hyperplasia.This treatment carries the risk of late thrombosis (due to delayed neoendotelization) the stent struts and requires rigorous long-term dual antiplatelet therapy with the risk of bleeding complications. The drug-coated balloon catheters provide short-term penetration of the active substance into the vascular wall, leading to the inhibition of hyperproliferation vascular smooth muscle cells, but due to short-term effect they do not affect negatively stent struts neoendotelization. Comparable effects of in-stent restenosis therapy using paclitaxel releasing balloons was demonstrated in comparison with paclitaxel releasing stents, however, the development of drug eluting stents meanwhile progressed. The aim of our study is to compare efficacy of coronary in-stent restenosis therapy using drug eluting paclitaxel-coated balloon catheters with the latest generation of drug eluting stents releasing everolimus. Primary endpoint of our study is late lumen loss, because it represents accurate angiographic parameter predicting the need for repeat revascularisation and thus the clinical benefit for the patient. The 3rd observational, non-randomised arm compares the treatment with seal-wing paclitaxel-eluting balloon with two randomised arms (PEB vs. EES). 3-year long term clinical follow-up of iopromide-coated PEB and EES arms was performed. All clinical MACE (CV death, AMI and TVR) were recorded. Subanalysis of seal-wing PEB arm comparrng the treatment of BMS and DES-ISR was added. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01735825
Study type Interventional
Source University Hospital Ostrava
Contact
Status Completed
Phase N/A
Start date January 2012
Completion date June 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01970579 - Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter Phase 3
Completed NCT01861860 - OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA N/A
Completed NCT01722877 - JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions N/A
Recruiting NCT00774917 - Numen Stent Assessment Using OCT Technique in a Single Center Study Phase 2/Phase 3
Completed NCT00493597 - Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of In-stent Restenosis
Completed NCT00647504 - Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis N/A
Not yet recruiting NCT01476020 - Is There A LIfe for Drug Eluting Stent (DES) After Discontinuation of Clopidogrel Phase 3
Terminated NCT00780156 - The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel N/A
Terminated NCT00712257 - Study to Evaluate the Safety and Performance of Spectranetics Laser w/Adjunct PTA and Gore Viabahn Endoprosthesis for Treatment of SFA Instent Restenosis N/A
Completed NCT01065532 - SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study N/A
Recruiting NCT03613337 - Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention
Completed NCT03332264 - Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions N/A
Completed NCT02063672 - Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis N/A
Recruiting NCT05451368 - Neointimal Features in Patients With Restenosis of Calcified Lesions
Completed NCT02649946 - Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft N/A
Completed NCT01632371 - Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4 Phase 4
Completed NCT00798954 - Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial Phase 4
Withdrawn NCT03146221 - Search for Restenosis Markers in Lower Limb Arteritis N/A
Completed NCT02790606 - Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA) N/A
Completed NCT01405248 - Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting Phase 3